Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of February 2025, with a specific reporting date of February 12, 2025. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a regulatory disclosure of insider share transactions.
Material Changes and Transactions
The filing details two specific transactions executed on February 11, 2025, on the London Stock Exchange (XLON) involving the acquisition of Partnership Shares and the award of Matching Shares under the Company's Share Reward Plan:
- Adrian Morris (General Counsel - PDMR): Acquired 32 Ordinary Shares at a price of £3.9249 per share. Additionally received 32 Matching Shares at a price of £Nil. Total aggregated volume: 64 shares.
- Tamara Rogers (Chief Marketing Officer - PDMR): Acquired 32 Ordinary Shares at a price of £3.9249 per share. Additionally received 32 Matching Shares at a price of £Nil. Total aggregated volume: 64 shares.
The financial instrument involved is Ordinary Shares of £0.01 each (ISIN: GB00BMX86B70).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is a routine compliance filing regarding executive shareholdings.
Key Facts for Investor Verification
- Verify the share price of £3.9249 against the market price on February 11, 2025.
- Confirm the terms of the Share Reward Plan regarding the matching share mechanism.
- Note that these transactions represent standard compensation-related acquisitions rather than open market trading by executives.
- Recognize that this filing does not contain updated financial results or strategic updates for the company.